1-substituted indazole derivative

Patent metadata

Field	Value
Publication number	US-9051295-B2
Application number	US-201314137904-A
Country	US
Kind code	B2
Filing date	Dec 20, 2013
Priority date	Apr 10, 2012
Publication date	Jun 9, 2015
Grant date	Jun 9, 2015

Abstract

A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I):

wherein A is CR 1E or a nitrogen atom, X—Y—Z is N—CO—NR 3A R 3B and the like, R 1A to R 1E are each independently a hydrogen atom and the like, R 2A to R 2D are each independently a hydrogen atom and the like, R 3A and R 3B are each independently an optionally-substituted C 3-10 cycloalkyl and the like, and n is 1 or 2

or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of α7 nicotinic acetylcholine receptor (α7 nAChR).

First claim

The invention claimed is:

1. A compound selected from the group consisting of:
N-(trans-4-methoxycyclohexyl)-4-[5-( 2 H 3 )methyl-1H-indazol-1-yl]piperidine-1-carboxamide;
N-(tetrahydro-2H-pyran-4-yl)-4-[5-(trifluoromethoxy)-1H-indazol-1-yl]piperidine-1-carboxamide; and
4-(5-methyl-1H-indazol-1-yl)-N-{trans-4-[( 2 H 3 )methoxy]cyclohexyl}piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the comp…

Assignees

• Dainippon Sumitomo Pharma Co
• Sumitomo Dainippon Pharma Co Ltd

Inventors

• Yamaguchi Hiroki
• Usui Shinya
• Nakai Yoko

Classifications

• A61P43/00

  Human Necessities · mapped topic

• A61P25/18

  Human Necessities · mapped topic

• A61P29/00

  Human Necessities · mapped topic

• A61P25/28

  Human Necessities · mapped topic

• C07D471/04 Primary

  Chemistry & Metallurgy · mapped topic